Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 17;2(6):732–746. doi: 10.1002/hep4.1181

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

The combination of ceritinib and sorafenib inhibited HCC cell growth by inhibiting the IGF1R/AKT pathway. (A) Expressions of p‐IGF1R, IGF1R, p‐AKT, AKT, and GAPDH proteins in Hep3B, HepG2, and Huh7 cells following treatment with DMSO, sorafenib, ceritinib, or a combination of both drugs for 24 hours were examined by western blotting. (B) Hep3B cells infected with control or constitutively active AKT lentiviral particles were treated with DMSO, ceritinib, sorafenib, or a combination of both drugs for 48 hours. Cells were then cultured for 14 days and stained with 0.5% crystal violet. (C) Colonies from (B) were quantified. Each experiment was repeated at least 3 times. Abbreviations: C, ceritinib; D, dimethyl sulfoxide; DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde 3‐phosphate dehydrogenase; S, sorafenib. Values in C were mean ± SD (n = 3 in each group).